F. de Marinis

发表

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

G. Scagliotti, C. Gridelli, M. Rinaldi, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Journal of Experimental & Clinical Cancer Research Positron Emission Tomography (pet) Radiotracers in Oncology – Utility of 18f-fluoro-deoxy-glucose (fdg)-pet in the Management of Patients with Non-small-cell Lung Cancer (nsclc)

A. Zullo, F. de Marinis, E. Miele, 2008 .

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.

F. de Marinis, F. Grossi, 2008, The oncologist.

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.

H. Wakelee, E. Smit, T. Mok, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

A. Chella, C. Gridelli, F. de Marinis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

B. Gyawali, F. de Marinis, A. Passaro, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

F. Cappuzzo, F. de Marinis, F. Grosso, 2020, Cancers.

A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.

F. de Marinis, A. Mancuso, E. Cortesi, 2004, Lung cancer.

Neoadjuvant strategies for non-small cell lung cancer.

F. de Marinis, A. Mancuso, L. de Petris, 2004, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.

S. Donghi, Juliana Guarize, L. Spaggiari, 2015, American journal of clinical pathology.

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.

G. Giaccone, R. Herbst, E. Felip, 2021, Journal of Thoracic Oncology.

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features

D. Galetta, S. Novello, F. de Marinis, 2021, Cancers.

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data.

F. de Marinis, L. Gianoncelli, G. Curigliano, 2020, Cancer treatment reviews.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

S. Barni, V. Torri, S. Novello, 2014, The Lancet. Oncology.

Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between

F. de Marinis, U. Malapelle, A. Passaro, 2020, Cancer.

Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.

T. Mok, S. Peters, F. de Marinis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics

Juliana Guarize, L. Spaggiari, F. de Marinis, 2018, Journal of Clinical Pathology.

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Edward S. Kim, Keunchil Park, F. de Marinis, 2022, Frontiers in Oncology.

Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: a systematic review

M. Casiraghi, L. Spaggiari, F. de Marinis, 2021, Translational lung cancer research.

New Agents in Advanced Non-Small-Cell Lung Cancer Treatment

F. de Marinis, S. Ricciardi, 2010, Oncology.

Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer

D. Galetta, L. Spaggiari, F. de Marinis, 2022, Cancers.

Proposals for revisions of the classification of lung cancers with multiple pulmonary sites: the radiologist's, thoracic surgeon's and oncologist's point of view.

F. Petrella, F. de Marinis, S. Rizzo, 2016, Journal of thoracic disease.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang, F. de Marinis, J. Wolf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular features and clinical outcome of lung malignancies in very young people.

L. Spaggiari, F. de Marinis, T. De Pas, 2015, Future oncology.

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.

F. de Marinis, V. Gebbia, L. de Petris, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer.

F. de Marinis, M. Migliorino, O. Martelli, 2002, Lung cancer.

Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.

F. de Marinis, A. Passaro, I. Attili, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.

S. Barni, C. Gridelli, F. de Marinis, 2007, Critical reviews in oncology/hematology.

The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

F. Petrella, G. Pelosi, Juliana Guarize, 2017, Journal of thoracic disease.

Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer.

A. Rossi, C. Gridelli, F. de Marinis, 2011, Clinical lung cancer.

Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer.

F. de Marinis, L. Crinò, M. Tonato, 2002, Lung cancer.

A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer

A. Rossi, F. de Marinis, M. Tiseo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.

G. Scagliotti, H. Kuo, F. de Marinis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The Role of Extended Pulmonary Metastasectomy

F. Petrella, M. Casiraghi, Juliana Guarize, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.

G. Scagliotti, A. Rossi, C. Gridelli, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.

D. de Ruysscher, S. Novello, E. Felip, 2020, Lung cancer.

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

C. Gridelli, F. de Marinis, Manali I. Patel, 2017, PloS one.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

C. Gridelli, L. Cavanna, F. de Marinis, 2013, Lung cancer.

Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT).

A. Rossi, C. Gridelli, F. de Marinis, 2010, Lung cancer.

Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma

M. Sormani, F. de Marinis, P. Bruzzi, 2007, Tumori.

Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma

C. Gridelli, A. Ceribelli, F. de Marinis, 2003, Cancer.

Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series.

L. Spaggiari, F. de Marinis, R. Orecchia, 2020, Neoplasma.

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

F. de Marinis, L. Travaini, M. Barberis, 2016, Clinical lung cancer.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

F. Cappuzzo, F. de Marinis, L. Crinò, 2019, Lung cancer.

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel

K. Nackaerts, F. de Marinis, K. Syrigos, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

F. Cappuzzo, L. Livi, F. de Marinis, 2018, European journal of cancer.

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way

L. Spaggiari, F. de Marinis, A. Passaro, 2020, Annals of translational medicine.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

Cellular and molecular biology of small cell lung cancer: an overview.

F. de Marinis, R. Rosell, S. Pilotto, 2016, Translational lung cancer research.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.

F. de Marinis, R. Danesi, F. Cucchiara, 2022, Clinical lung cancer.

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

F. de Marinis, A. Passaro, G. Spitaleri, 2016, Expert review of anticancer therapy.

Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.

U. Pastorino, S. Novello, F. de Marinis, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases

M. Bignardi, G. Veronesi, F. de Marinis, 2020, Archives of Public Health.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to S. Barni et Al, K.R. Dearing et al, and N. Murray.

C. Gridelli, F. de Marinis, L. Paz-Ares, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer.

F. de Marinis, S. Clarke, A. Passaro, 2013, Lung cancer.

Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

R. Labianca, C. Tibaldi, E. Smit, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.

S. Novello, F. de Marinis, R. Dziadziuszko, 2020, Lung cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Miklos Pless, N. Hanna, C. Desch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.

A. Chella, A. Rossi, C. Gridelli, 2016, Anticancer research.

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.

C. Gridelli, F. de Marinis, P. Baas, 2015, Clinical lung cancer.

Long-term disease-free survival of a patient with synchronous bilateral lung adenocarcinoma displaying different EGFR and C-MYC molecular characteristics.

F. de Marinis, P. Graziano, A. Mancuso, 2011, Chest.

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review

F. de Marinis, G. Viale, G. Curigliano, 2021, Current oncology.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

G. Giaccone, N. Reinmuth, R. Herbst, 2020, The New England journal of medicine.

Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients

S. Barni, A. Brandes, C. Gridelli, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Testing for COVID-19 in lung cancer patients

T. Mitsudomi, T. Mok, F. de Marinis, 2020, Annals of Oncology.

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.

G. Scagliotti, C. Tibaldi, M. Rinaldi, 2009, Lung cancer.

Role of Induction Chemotherapy in Resectable N2 Non-small Cell Lung Cancer

F. de Marinis, S. De Santis, M. Migliorino, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease.

F. de Marinis, S. De Santis, L. de Petris, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC

E. Felip, F. de Marinis, R. Rosell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).

S. Barni, S. Novello, F. de Marinis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer surgery in oligometastatic patients: outcome and survival.

F. Petrella, M. Casiraghi, D. Galetta, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses

F. de Marinis, N. Mazzanti, Carolina Scauri, 2019, Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish.

F. de Marinis, A. Passaro, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of target coverage and margins adequacy during CyberKnife Lung Optimized Treatment

L. Spaggiari, F. de Marinis, M. Riboldi, 2018, Medical physics.

EGFR Inhibitors: Clinical Results

F. de Marinis, G. D’Auria, F. Nelli, 2002, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy.

F. de Marinis, A. Mancuso, S. De Santis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study

F. Petrella, M. Casiraghi, Juliana Guarize, 2021, Journal of clinical medicine.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Keunchil Park, F. de Marinis, J. von Pawel, 2019, Lung cancer.

Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials.

F. de Marinis, A. Passaro, I. Attili, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.

F. de Marinis, A. Passaro, I. Attili, 2021, The Lancet. Oncology.

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

M. Tsuboi, Jie He, R. Herbst, 2020, The New England journal of medicine.

Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology

C. Gridelli, L. Spaggiari, F. de Marinis, 2022, Frontiers in Oncology.

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

A. Shaw, T. Mok, E. Felip, 2020, The New England journal of medicine.

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

F. de Marinis, A. Passaro, G. Antonarelli, 2022, Frontiers in Oncology.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases

F. de Marinis, A. Santoro, P. Marchetti, 2019, AntiCancer Research.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

A. Chella, F. Cappuzzo, D. Galetta, 2019, The oncologist.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.

L. Spaggiari, F. de Marinis, R. Orecchia, 2022, Cancer treatment reviews.

Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer

Juliana Guarize, L. Spaggiari, F. de Marinis, 2022, Frontiers in Oncology.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

F. Cappuzzo, D. de Ruysscher, S. Novello, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

F. Cappuzzo, D. de Ruysscher, S. Novello, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.

F. Cappuzzo, D. de Ruysscher, D. Ruysscher, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

G. Scagliotti, F. de Marinis, L. Crinò, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

F. de Marinis, G. Curigliano, C. Santoro, 2022, Clinical Lung Cancer.

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study

F. Cappuzzo, F. de Marinis, F. Grosso, 2019, Cancers.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Surgery for small cell lung cancer: When and how.

F. Petrella, M. Casiraghi, L. Spaggiari, 2020, Lung cancer.

Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations.

M. Ahn, T. Mok, S. Peters, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

S. Peters, E. Felip, F. de Marinis, 2020, ESMO Open.

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.

F. de Marinis, A. Mancuso, E. Cortesi, 2004, The oncologist.

Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.

G. Scagliotti, C. Gridelli, M. Rinaldi, 1998, Seminars in oncology.

Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.

F. de Marinis, S. Ricciardi, 2009, Reviews on recent clinical trials.

Reply.

F. de Marinis, A. Passaro, G. Spitaleri, 2020, Clinical lung cancer.

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.

A. Shaw, E. Felip, F. de Marinis, 2022, Lung cancer.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of Thoracic Oncology.

Brain metastases from NSCLC treated with stereotactic radiotherapy: prediction mismatch between two different radiomic platforms.

V. Positano, L. Spaggiari, F. de Marinis, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

A. Shaw, T. Mok, Yi-long Wu, 2022, The Lancet. Respiratory medicine.

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

F. de Marinis, S. Ricciardi, A. Passaro, 2014, Therapeutic advances in medical oncology.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

J. Engelman, A. Shaw, B. Yeap, 2015, Clinical Cancer Research.

Induction Therapy with Paclitaxel and Carboplatin Followed by Hyperfractionated Radiotherapy plus Weekly Concurrent Chemotherapy and Subsequent Consolidation Therapy in Unresectable Locallyadvanced Non-Small-Cell Lung Cancer

F. de Marinis, U. de Paula, L. Moscetti, 2007 .

Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer.

F. de Marinis, U. de Paula, L. Moscetti, 2007, Tumori.

Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.

C. Gridelli, F. de Marinis, M. Aita, 2008, Critical reviews in oncology/hematology.

Understanding EGFR heterogeneity in lung cancer

L. Spaggiari, F. de Marinis, G. Troncone, 2020, ESMO Open.

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.

H. Wakelee, E. Smit, T. Mok, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

C. Gridelli, K. Kelly, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

C. Gridelli, F. de Marinis, A. Ardizzoni, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

H. Ditzel, F. de Marinis, R. Rosell, 2017, Journal of the National Cancer Institute.

Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.

L. Spaggiari, F. de Marinis, D. Planchard, 2020, Lung cancer.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, The Lancet. Oncology.

erbB in NSCLC as a molecular target: current evidences and future directions

A. Chella, F. de Marinis, R. Danesi, 2020, ESMO Open.

Ensartinib (X-396) a novel drug for anaplastic lymphoma kinasepositive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets.

F. de Marinis, A. Passaro, G. Spitaleri, 2019, Chinese clinical oncology.

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.

A. Rossi, C. Gridelli, F. de Marinis, 2016, Clinical lung cancer.

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

F. de Marinis, S. Gandini, F. Bertolini, 2019, Clinical and Translational Oncology.

Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice

C. Gridelli, S. Gasparini, F. de Marinis, 2019, Expert review of respiratory medicine.

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients

E. Vasile, G. Fasola, D. Galetta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?

F. de Marinis, P. Conte, A. Pavan, 2017, Critical reviews in oncology/hematology.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

F. Cappuzzo, C. Gridelli, F. de Marinis, 2017, Translational lung cancer research.

Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

P. Ascierto, C. Gridelli, E. Felip, 2016, Expert opinion on biological therapy.

Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer

L. Spaggiari, F. de Marinis, G. Bertalot, 2016, Oncotarget.

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion

G. Giaccone, R. Gelber, C. Swanton, 2021, Clinical Cancer Research.

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

F. de Marinis, R. Rosell, B. Massuti, 2014, Translational lung cancer research.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

F. de Marinis, L. Preda, M. Barberis, 2014, OncoTargets and therapy.

Treatment of advanced non-small cell lung cancer.

G. Scagliotti, C. Gridelli, D. Galetta, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

F. de Marinis, A. Rappa, M. Barberis, 2017, Pharmacological research.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

F. Cappuzzo, C. Gridelli, T. Mok, 2011, Lung cancer.

Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

N. Hanna, C. Gridelli, E. Felip, 2017, Clinical lung cancer.

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

G. Bepler, G. Scagliotti, F. de Marinis, 2003, Seminars in Oncology.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

N. Pavlakis, A. Shaw, T. Mok, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.

F. de Marinis, V. De Luca, M. Barberis, 2018, Archives of pathology & laboratory medicine.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, Michael Thomas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

M. Tsao, F. de Marinis, C. Barrios, 2018, PloS one.

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer

F. Shepherd, F. de Marinis, T. John, 2023, PharmacoEconomics - Open.

Application of nnU-Net for Automatic Segmentation of Lung Lesions on CT Images and Its Implication for Radiomic Models

D. Origgi, L. Spaggiari, F. de Marinis, 2022, Journal of clinical medicine.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.

A. Marchetti, F. Buttitta, F. Mucilli, 2017, JCO precision oncology.

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.

F. Cappuzzo, F. de Marinis, G. Ceresoli, 2021, The Lancet. Oncology.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

F. Cappuzzo, F. de Marinis, F. Mazzoni, 2016, Lung cancer.

Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma

F. Petrella, M. Casiraghi, D. Galetta, 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

F. de Marinis, V. Moreno, A. Hollebecque, 2017, European journal of cancer.

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy

C. Porta, A. Chella, F. de Marinis, 2019, International journal of molecular sciences.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

F. Cappuzzo, C. Gridelli, F. Hirsch, 2014, Clinical lung cancer.

Toxicity of targeted therapy in non-small-cell lung cancer management.

F. de Marinis, S. Tomao, S. Ricciardi, 2009, Clinical lung cancer.

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer

Massimo Bellomi, Francesco Petrella, Lorenzo Spaggiari, 2015, European Radiology.

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)

C. Gridelli, F. de Marinis, N. Normanno, 2020, Cancers.

New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.

F. de Marinis, S. Ricciardi, E. del Signore, 2012, Future oncology.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

C. Gridelli, F. de Marinis, L. Crinò, 2008, Critical reviews in oncology/hematology.

Afatinib in NSCLC harbouring EGFR mutations.

F. de Marinis, A. Passaro, C. Catania, 2014, The Lancet. Oncology.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Gridelli, F. de Marinis, L. Paz-Ares, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

J. Bogaerts, F. de Marinis, J. von Pawel, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).

C. Tibaldi, M. Rinaldi, F. de Marinis, 1998, British Journal of Cancer.

Combination of chemotherapy and recombinant alpha‐interferon in advanced non‐small cell lung cancer: Multicentric randomized FONICAP trial report

G. Scagliotti, M. Rinaldi, F. de Marinis, 1993, Cancer.

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

C. Specchia, F. de Marinis, P. Queirolo, 2020, JNCI cancer spectrum.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical Lung Cancer.

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non‐Small Cell Lung Cancer: The Role of Cancer Stem Cells

F. de Marinis, R. Danesi, A. Di Paolo, 2018, Stem cells.

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

F. de Marinis, M. Barberis, C. Fumagalli, 2015, OncoTargets and therapy.

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2015, Clinical lung cancer.

Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).

C. Gridelli, F. Hirsch, F. de Marinis, 2014, International journal of oncology.

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.

F. de Marinis, P. Bruzzi, A. Ardizzoni, 1995, British Journal of Cancer.

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

G. Scagliotti, A. Ceribelli, S. Novello, 2005, British Journal of Cancer.

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.

G. Scagliotti, M. Rinaldi, S. Novello, 2005, Lung cancer.

Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.

F. Cappuzzo, F. de Marinis, L. Crinò, 2003, Lung cancer.

Quality of life in lung cancer patients.

C. Gridelli, F. de Marinis, F. Perrone, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.

G. Scagliotti, C. Gridelli, M. Rinaldi, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

C. Gridelli, Michael Thomas, F. de Marinis, 2012, The Lancet. Oncology.

Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.

L. Spaggiari, F. de Marinis, R. Orecchia, 2020, Lung cancer.

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

A. Chella, L. Landi, G. Alí, 2019, Clinical Cancer Research.

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients

F. de Marinis, G. Viale, M. Barberis, 2019, Journal of clinical medicine.

Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a ‘no-fly zone’?

L. Spaggiari, F. de Marinis, R. Orecchia, 2018, Acta oncologica.

The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2016, Clinical lung cancer.

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2015, Scientific Reports.

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

G. Fontanini, F. Cappuzzo, C. Gridelli, 2014, Journal of Cancer Research and Clinical Oncology.

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.

F. de Marinis, G. Tortora, M. Brunelli, 2014, Critical reviews in oncology/hematology.

Second-line treatment options in advanced non-small cell lung cancer.

F. de Marinis, S. Ricciardi, 2011, European journal of cancer.

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.

S. Barni, G. Scagliotti, C. Gridelli, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

F. de Marinis, U. Malapelle, P. Pisapia, 2022, Current oncology.

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

L. Landi, F. Cappuzzo, F. de Marinis, 2019, Clinical lung cancer.

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials.

D. Galetta, F. de Marinis, V. Gebbia, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

F. Cappuzzo, C. Gridelli, F. de Marinis, 2010, The oncologist.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

F. Cappuzzo, C. Gridelli, T. Mok, 2011, Lung cancer.

Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors

F. de Marinis, M. Barberis, F. Conforti, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

F. de Marinis, R. Rosell, N. Karachaliou, 2016, OncoTargets and therapy.

Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer

F. de Marinis, S. Ricciardi, E. del Signore, 2012, Expert opinion on therapeutic targets.

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.

S. Barni, C. Gridelli, F. de Marinis, 2011, Lung cancer.

Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.

F. de Marinis, S. Tomao, S. Ricciardi, 2010, Lung Cancer.

Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.

F. de Marinis, A. Passaro, 2019, Translational lung cancer research.

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.

F. de Marinis, A. Passaro, 2018, Translational lung cancer research.

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data

F. de Marinis, C. Noberasco, A. Passaro, 2016, Expert review of clinical pharmacology.

Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

F. de Marinis, C. Noberasco, A. Passaro, 2016, Journal of Thoracic Disease.

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.

G. Fontanini, F. Cappuzzo, C. Gridelli, 2014, Clinical lung cancer.

management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.

F. de Marinis, M. Di Maio, A. Passaro, 2014, Clinical lung cancer.

Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.

F. de Marinis, A. Passaro, B. Gori, 2013, Journal of thoracic disease.

Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.

A. Rossi, C. Gridelli, F. de Marinis, 2011, Lung cancer.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.

F. Cappuzzo, C. Gridelli, R. Stahel, 2012, Lung cancer.

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options

F. Petrella, M. Casiraghi, L. Spaggiari, 2023, Current oncology.

International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes

D. Lambrechts, C. Gridelli, E. Smit, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

F. de Marinis, S. Ricciardi, A. Fulvi, 2011, Therapeutics and clinical risk management.

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

E. Karapanagiotou, F. de Marinis, M. Saif, 2011, Anticancer research.

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

R. Gasparri, L. Spaggiari, F. de Marinis, 2018, Journal of thoracic disease.

Pemetrexed in the treatment of advanced non-squamous lung cancer.

A. Rossi, C. Gridelli, F. de Marinis, 2009, Lung cancer.

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first‐line treatment in patients with poor‐prognosis small cell lung carcinoma

S. Barni, R. Labianca, C. Gridelli, 2005, Cancer.

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

C. Dooms, F. de Marinis, J. Mazières, 2022, Annals of Oncology.

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

M. Fassan, F. de Marinis, R. Rosell, 2020, Translational lung cancer research.

Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study.

A. Ceribelli, F. de Marinis, A. Mancuso, 2005, Anticancer research.

Bone metastases and non-small cell lung cancer: from bisphosphonates to targeted therapy.

A. Rossi, C. Gridelli, F. de Marinis, 2012, Current medicinal chemistry.

Multimodality management of non-small cell lung cancer patients with brain metastases

F. de Marinis, S. Ricciardi, 2010, Current opinion in oncology.

Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study

F. Petrella, M. Casiraghi, L. Spaggiari, 2023, Journal of clinical medicine.

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

G. Scagliotti, P. Navarria, F. de Marinis, 2016, Lung Cancer.

Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.

M. Maltoni, M. Pirovano, O. Nanni, 1997, Journal of pain and symptom management.

The Role of Vindesine and Lonidamine in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer: A Phase III Randomized Fonicap Trial

M. Rinaldi, F. de Marinis, G. Altavilla, 1999, Tumori.

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study.

A. Rossi, C. Gridelli, F. de Marinis, 1997, European journal of cancer.

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

K. O'Byrne, F. de Marinis, J. von Pawel, 2011, The Lancet. Oncology.

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

S. Barni, R. Labianca, G. Luporini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

F. de Marinis, E. Cortesi, A. Passaro, 2011, Expert review of anticancer therapy.

Strategies to overcome resistance to immune checkpoint blockade in lung cancer.

F. de Marinis, G. Curigliano, P. Tarantino, 2021, Lung cancer.

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial

G. Scagliotti, C. Gridelli, M. Rinaldi, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

F. de Marinis, S. Tomao, S. Ricciardi, 2009, Therapeutics and clinical risk management.

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

N. Hanna, C. Gridelli, F. Shepherd, 2010, Lung cancer.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, Lung cancer.

The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies

F. de Marinis, G. Troncone, R. Danesi, 2021, Expert review of molecular diagnostics.

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey

D. Radice, F. de Marinis, L. Gianoncelli, 2020, Frontiers in Oncology.

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

C. Gridelli, S. Peters, F. de Marinis, 2021, ESMO open.

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

F. de Marinis, G. Ceresoli, R. Ramlau, 2021, ESMO open.

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

G. Giaccone, C. Gridelli, T. Mok, 2018, ESMO Open.

Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.

C. Gridelli, L. Cavanna, F. de Marinis, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

L. Sequist, S. Novello, F. de Marinis, 2022, Journal of Thoracic Oncology.

Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding.

F. de Marinis, L. Gianoncelli, V. Stati, 2019, Annals of translational medicine.

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

M. Tsuboi, F. de Marinis, M. Tiseo, 2022, ESMO open.

Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.

F. de Marinis, S. Bonassi, P. Granone, 2006, Lung cancer.

The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review

F. Petrella, M. Casiraghi, D. Galetta, 2023, Cancers.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

F. de Marinis, C. Grohé, Y. Wu, 2022, Annals of Oncology.

EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.

A. Brandes, C. Gridelli, F. de Marinis, 2017, Anticancer research.

Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

R. Labianca, C. Tibaldi, E. Smit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.

R. Stahel, F. de Marinis, D. Betticher, 2004, European journal of cancer.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

H. Groen, G. Scagliotti, H. Wakelee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.

R. Gelber, F. de Marinis, A. Goldhirsch, 2019, Journal of the National Cancer Institute.

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations

L. Spaggiari, F. de Marinis, A. Rappa, 2021, Cancers.

Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis

D. Radice, F. de Marinis, L. Gianoncelli, 2020, AntiCancer Research.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of image filtering and assessment of volume-confounding effects on CT radiomic features and derived survival models in non-small cell lung cancer

L. Spaggiari, F. de Marinis, R. Orecchia, 2021, Translational lung cancer research.

Phase II Study of Taxol Combined With Ifosfamide and Carboplatin in the Treatment of Stage IIIb–IV Non-Small-Cell Lung Cancer

V. Torri, F. de Marinis, C. Boni, 2003, American journal of clinical oncology.

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.

F. de Marinis, S. Walzer, F. Grossi, 2010, Lung cancer.

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression

G. Giaccone, R. Herbst, F. de Marinis, 2021, Frontiers in Oncology.

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

U. Dafni, E. Smit, A. Dingemans, 2022, Lung cancer.

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.

A. Rossi, C. Gridelli, F. de Marinis, 2007, The oncologist.

Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.

L. Spaggiari, A. Cancellieri, F. de Marinis, 2023, Clinical lung cancer.

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

F. de Marinis, C. Corti, E. Crimini, 2023, Current oncology.

Pneumonectomy in Stage IIIA‐N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

C. Gridelli, F. Petrella, M. Casiraghi, 2019, Clinical lung cancer.

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

F. de Marinis, S. Walzer, J. de Castro Carpeno, 2011, Lung cancer.

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model

L. Spaggiari, F. de Marinis, L. Gianoncelli, 2020, Frontiers in Oncology.

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.

G. Scagliotti, F. Cappuzzo, S. Novello, 2006, Lung cancer.

Bisphosphonates: prevention of bone metastases in lung cancer.

K. Nackaerts, F. de Marinis, K. Syrigos, 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.

M. Tsuboi, T. Mok, F. de Marinis, 2023, JAMA oncology.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib

F. Cappuzzo, G. Fasola, F. de Marinis, 2019, Cancers.

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Multidisciplinary Team Meetings on Patient Management in Oncologic Thoracic Surgery: A Single-Center Experience

D. Radice, F. Petrella, L. Spaggiari, 2021, Cancers.

Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).

M. Socinski, J. Hainsworth, T. Lynch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

F. de Marinis, Dae-Ho Lee, H. Isobe, 2018, BMC Health Services Research.

Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.

Edward S. Kim, M. Ahn, S. Novello, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences

K. Nackaerts, G. Pravettoni, I. Durosini, 2021, Frontiers in Pharmacology.

Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).

C. Gridelli, F. de Marinis, I. Attili, 2023, ESMO open.

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2023, Scientific Reports.

Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy‐proven Stage IIIA(N2) nonsmall cell lung carcinoma

C. Gridelli, F. de Marinis, E. Cortesi, 2003, Cancer.

M. Tsuboi, R. Herbst, Yi-long Wu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma

G. Scagliotti, F. Cappuzzo, S. Novello, 2003, Cancer.

Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.

F. Petrella, M. Casiraghi, L. Spaggiari, 2016, Seminars in thoracic and cardiovascular surgery.

Identification of EGFR mutations in lung sarcomatoid carcinoma

F. de Marinis, P. Graziano, A. Mancuso, 2011, International journal of cancer.

EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.

G. Pelosi, F. de Marinis, P. Graziano, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Keunchil Park, Yi-long Wu, F. de Marinis, 2021, Frontiers in Oncology.

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.

F. de Marinis, E. Cortesi, S. Gasperoni, 2003, Lung cancer.

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.

F. de Marinis, C. Rampinelli, A. Passaro, 2017, American journal of respiratory and critical care medicine.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.

F. de Marinis, A. Passaro, G. Spitaleri, 2023, Cancer treatment reviews.

57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results

F. de Marinis, M. Schenker, M. Reck, 2022, Immuno-Oncology and Technology.

Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC).

G. Scagliotti, C. Gridelli, S. Novello, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making.

F. de Marinis, M. Barberis, A. Passaro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety Analysis of Salvage Surgery for Advanced Stages or Metastatic Lung Cancers

D. Galetta, L. Spaggiari, F. de Marinis, 2021, The Thoracic and Cardiovascular Surgeon.

Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy

L. Spaggiari, F. de Marinis, R. Orecchia, 2023, Cancers.

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

F. de Marinis, D. Gultyaev, S. Walzer, 2015, Expert review of anticancer therapy.

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2018, Current medical research and opinion.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

P. Ascierto, A. Rossi, C. Gridelli, 2018, Current clinical pharmacology.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Clinical lung cancer.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

E. Vasile, S. Barni, D. Galetta, 2015, Scientific Reports.

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of Clinical Oncology.

Predictors, surrogate, and patient-reported outcomes in immunotherapy and salvage surgery for unresectable lung cancer: a single-center retrospective study

F. Petrella, M. Casiraghi, D. Galetta, 2023, Updates in Surgery.

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Jie Yang, Gregory Riely, F. de Marinis, 2023, Journal of Clinical Oncology.

LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

P. Jänne, E. Felip, F. de Marinis, 2022, Immuno-Oncology and Technology.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Six-Drug Sequential Chemotherapy in Non Small Cell Lung Cancer. A North Milan Group Study

F. Lombardi, F. de Marinis, A. Libretti, 1988, Tumori.

Quality of life in lung cancer patients.

C. Gridelli, F. de Marinis, F. Perrone, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.

F. Cappuzzo, F. de Marinis, G. Ceresoli, 2020 .

A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer.

A. Rossi, C. Gridelli, F. de Marinis, 1997, Anticancer research.

F. de Marinis, G. Tortora, M. Brunelli, 2014, Critical reviews in oncology/hematology.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical lung cancer.

Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.

F. de Marinis, F. Grossi, 2008, The oncologist.

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

F. de Marinis, R. Rosell, A. Vergnenègre, 2015, Future oncology.

Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients

F. de Marinis, R. Orecchia, B. Jereczek-Fossa, 2023, Cancers.

Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

S. Barni, V. Torri, S. Novello, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

F. de Marinis, M. Salzberg, J. Jassem, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

F. de Marinis, A. Passaro, G. Spitaleri, 2023, Cancers.

Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterfly.

F. de Marinis, V. Stati, A. Passaro, 2018, Pulmonology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.

C. Gridelli, F. de Marinis, P. Baas, 2015, Clinical lung cancer.

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel

K. Nackaerts, F. de Marinis, K. Syrigos, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.

F. de Marinis, Ji-Youn Han, L. Servidio, 2023, Clinical lung cancer.

Identification of EGFR mutations in lung sarcomatoid carcinoma

F. de Marinis, P. Graziano, A. Mancuso, 2011, International journal of cancer.

Pemetrexed in second-line treatment of non-small-cell lung cancer.

F. de Marinis, L. de Petris, 2004, Oncology.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

C. Gridelli, L. Cavanna, F. de Marinis, 2013, Lung cancer.

Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.

F. de Marinis, S. De Santis, L. de Petris, 2006, Seminars in oncology.

Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

C. Gridelli, F. de Marinis, I. Attili, 2023, Lung Cancer.